Where Are They Now? Lymphoma Rounds 15 Years In Review
Since 2008, Lymphoma Rounds programs provide a forum for healthcare professionals to meet regularly and address issues specific to the diagnosis and treatment of their lymphoma patients.
News
Tackling Obstacles On and Off the Field
In many ways, Timmy Ward is a typical college senior, majoring in sociology and playing football for the Rutgers Scarlet Knights – a Big Ten powerhouse. However, what most people don’t know is what he has had to overcome to get here.
Meet the 2024 Career Development Award and Postdoctoral Fellowship Research Grantees
The 16 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Mantle Cell Lymphoma
On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of…
Lymphoma Research Foundation Rebrands to Reflect Its Unifying Role Within the Lymphoma Community
The new visual identity for the Lymphoma Research Foundation symbolizes unity, vitality, and inclusivity within the lymphoma community. The rebranding also includes enhancements to the Foundation's digital platforms and resources, ensuring that patients, caregivers, physicians, researchers, and donors can easily access the information and support they need.
Lymphoma Research Foundation Funds 28 New Grants Supporting the Next Generation of Lymphoma Scientists
Lymphoma Research Foundation Funds 28 New Grants Supporting the Next Generation of Lymphoma Scientists New York, NY (May 20, 2024) – The Lymphoma Research Foundation (LRF), the nation’s largest nonprofit organization devoted to funding innovative lymphoma research and serving the…
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Follicular Lymphoma
On May 15, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic…
The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa, BeiGene USA, Inc.) with Obinutuzumab for Relapsed/Refractory Follicular Lymphoma (FL)
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two…
Celebrating the Original ‘Chemo Diva’
Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search for others like you who are going through a similar experience. That sense of community and support, of seeing your own story reflected to you,…
Where Are They Now? Ryan Lynch, MD
Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred Hutchinson Cancer Center. When did you become interested in the study of medicine? In lymphoma specifically? I had a great opportunity while I was in…